Cargando…

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales

BACKGROUND: Neonatal sepsis is a serious and frequently lethal infection, often complicated by antimicrobial resistance (including ESBLs) in low- and middle-income countries (LMICs). Flomoxef is an off-patent oxacephem β-lactam with stability against non-AmpC ESBLs, with potential for utility in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darlow, Christopher A, Hope, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864998/ https://www.ncbi.nlm.nih.gov/pubmed/34969066 http://dx.doi.org/10.1093/jac/dkab468

Ejemplares similares

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022)

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
por: Darlow, Christopher A, et al.
Publicado: (2022)

2778. Retrospective evaluation of effectiveness of Flomoxef for infections due to extended-spectrum β-lactamase-producing Enterobacterales
por: Koizumi, Ryuji, et al.
Publicado: (2023)

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria
por: Darlow, Christopher A., et al.
Publicado: (2021)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function
por: Hamada, Yukihiro, et al.
Publicado: (2022)

The Role of Virulence Factors in Neonatal Sepsis Caused by Enterobacterales: A Systematic Review
por: Barcellini, Lucia, et al.
Publicado: (2022)

The Genotypic and Phenotypic Characteristics Contributing to Flomoxef Sensitivity in Clinical Isolates of ESBL-Producing E. coli Strains from Urinary Tract Infections
por: Sakaeda, Kazuma, et al.
Publicado: (2023)

Risk factors for predicting extended-spectrum β-lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates
por: Burgoon, Rachel, et al.
Publicado: (2023)

Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
por: Horie, Akiyoshi, et al.
Publicado: (2019)

Carriage of ESBL-producing Enterobacterales in wastewater treatment plant workers and surrounding residents — the AWARE Study
por: Rodríguez-Molina, Daloha, et al.
Publicado: (2021)

Analysis of Extended Spectrum Beta Lactamase (ESBL) Genes of Non-Invasive ESBL Enterobacterales in Southeast Austria in 2017
por: Paulitsch-Fuchs, Astrid H., et al.
Publicado: (2022)

Detection of Extended-Spectrum β-Lactamases (ESBLs) and AmpC in Class A and Class B Carbapenemase-Producing Enterobacterales
por: Imkamp, Frank, et al.
Publicado: (2022)

In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
por: Yamashiro, Hidenori, et al.
Publicado: (2023)

Carriage and Acquisition of Extended-spectrum β-Lactamase–producing Enterobacterales Among Neonates Admitted to Hospital in Kilifi, Kenya
por: Kagia, Ngure, et al.
Publicado: (2019)

Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland
por: Kuch, Alicja, et al.
Publicado: (2020)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia
por: Yap, Polly Soo Xi, et al.
Publicado: (2023)

The potential role of microbiota for controlling the spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) in neonatal population
por: Delerue, Thibaud, et al.
Publicado: (2017)

Emergence of ST1193 Clone in Maternal and Neonatal ESBL-Producing E. coli Isolates
por: Wei, Ling, et al.
Publicado: (2023)

The Impact of COVID-19 Pandemic on ESBL-Producing Enterobacterales Infections: A Scoping Review
por: Mai, Ha Thi Thao, et al.
Publicado: (2023)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales
por: Tan, Xing, et al.
Publicado: (2021)

Treatment of infections caused by carbapenemase-producing Enterobacterales
por: Íñigo, Melania, et al.
Publicado: (2022)

2826. Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing Enterobacterales and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)
por: Fernandez, Maria, et al.
Publicado: (2023)

1225. Optimization of Antimicrobial Therapy for Extended-Spectrum β-Lactamase-Producing Enterobacterales (ESBL-E) Bloodstream Infections Through Laboratory-Based Interventions
por: Yazdi, Mona, et al.
Publicado: (2023)

In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia
por: Ngoi, Soo Tein, et al.
Publicado: (2021)

Monitoring of Non-β-Lactam Antibiotic Resistance-Associated Genes in ESBL Producing Enterobacterales Isolates
por: Shinu, Pottathil, et al.
Publicado: (2020)

Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases
por: Noster, Janina, et al.
Publicado: (2021)

Epidemiology and clinical characteristics of infection/colonization due to carbapenemase-producing Enterobacterales in neonatal patients
por: Wang, Jiansheng, et al.
Publicado: (2022)

Extended-interval Dosing of Gentamicin for Treatment of Neonatal Sepsis in Developed and Developing Countries
por: Darmstadt, Gary L., et al.
Publicado: (2008)

Neonatal Seizures: An Overview of Genetic Causes and Treatment Options
por: Spoto, Giulia, et al.
Publicado: (2021)

Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers
por: Singh, Bhoj R
Publicado: (2018)

Multidrug-Resistant and Extended-Spectrum β-Lactamase (ESBL) - Producing Enterobacterales Isolated from Carriage Samples among HIV Infected Women in Yaoundé, Cameroon
por: Zemtsa, Ravalona Jessica, et al.
Publicado: (2022)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales [Corrigendum]
Publicado: (2021)

1706. Risk factors for infections caused by extended spectrum beta lactamase (ESBL) producing and Carbapenem-resistant Enterobacterales (CRE) in pediatric critical care settings: A case control study
por: Omar, Amr, et al.
Publicado: (2023)

Prevalence of ESBL, AmpC and Carbapenemase-Producing Enterobacterales Isolated from Raw Vegetables Retailed in Romania
por: Colosi, Ioana Alina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vhkk98eb6nvq7mu6gle19juf6n